Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1373954 | 0.98 | SMN1; SMN2 (0.74) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL20676018 | 0.94 | SMN1; SMN2 (0.85) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL1902358 | 0.88 | SMN1; SMN2 (0.76) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL12741625 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2HTTHPGDL3MBTL1KMT2A | |
| SCHEMBL7459479 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL4844448 | 0.87 | HTT (0.58) | SMN1; SMN2HTTHPGDALDH1A1KMT2A | |
| SCHEMBL7465720 | 0.87 | HTT (1.00) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL7456756 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL13387703 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL7462557 | 0.84 | ALDH1A1 (0.71) | SMN1; SMN2HTTHPGDALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016153023-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | 国立研究開発法人国立長寿医療研究センター | 2016-09-29 | — | — | WO | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| EP-1180513-A1 | CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-2002012377-A2 | FLAME RETARDANT FOAM FROM BLENDS OF VINYL AROMATIC AND OLEFINIC POLYMERS | THE DOW CHEMICAL COMPANY (US) | 2002-02-14 | — | — | WO | disclosed |
| EP-1179341-A1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LIMITED (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0393607-B1 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMA CO LTD (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | SMN1; SMN2 199/4885HTT 113/4885HPGD 4517/4885 |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | APP, BACE1, PSEN1 | SMN1; SMN2 1103/4885HTT 18/4885HPGD 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.